ProCE Banner Activity

CE / CME

Paying Attention to Treatment-Related Adverse Events in ADHD

Video

On-demand webcast recording of the presentation on treatment-related adverse events in ADHD by Greg W. Mattingly, MD, held at the Second Annual Psychiatry Summit.

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Psychologists: 1.00 APA CE Credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Social Workers: 1.00 ASWB ACE CE Credit

Released: June 13, 2023

Expiration: June 12, 2024

No longer available for credit.

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Jonathan M. Meyer

Jonathan M. Meyer, MD, DLFAPA

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Senior Academic Adviser
California Department of State Hospitals
San Diego, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is not commercially supported.

Independent Educational Activity

Target Audience

This activity is intended for physicians, physician assistants/physician associates, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with psychiatric illness.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of psychiatric illness.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Distinguish ADHD treatment-related adverse events from comorbid conditions

  • Identify the impact/burden of treatment-related adverse events on quality of life of patients with ADHD

  • Incorporate evidence-based strategies for management of treatment-related adverse events into care plans for patients experiencing adverse events from their ADHD treatment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Ironshore, Intracellular, Janssen, Lumos Labs, Lundbeck, MedPoint, Neos, Neurocrine, Noven, Otsuka, Redax, Roche, Rhodes, Sage, Skye Therapeutics, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Akilli, Axsome, Boehringer Ingelheim, Corium, Emalex, Idorsida, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.

Jonathan M. Meyer, MD, DLFAPA

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Senior Academic Adviser
California Department of State Hospitals
San Diego, California

Jonathan Meyer, MD: consultant/advisor/speaker: Alkermes, Axsome, Cervel, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America, Relmada, Sunovion Pharmaceuticals, Teva Pharmaceuticals. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Gabrielle Giacona and Michael Asbach, DMSc, PA-C, Psych-CAQ, as noted below.

Gabrielle Giacona: stock/stock options: AstraZeneca, Moderna.

Michael Asbach, DMSc, PA-C, Psych-CAQconsultant/advisor/speaker: AbbVie, Avanir, Biogen, Janssen, Karuna, Neurocrine, Otsuka.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 13, 2023, through June 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint Accreditation

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education

CCO designates this enduring material  for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacology credit. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number -  JA4008176-0000-23-162-H01-P 

Type of Activity: Application 

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 12, 2024. PAs should only claim commensurate with the extent of their participation.

Social Work Continuing Education


As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 clinical continuing education credit.

Psychologist Continuing Education

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity offers 1 continuing education credit for psychologists.